Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Yansong Lin,Shukui Qin,Hui Yang,Feng Shi,Aimin Yang,Xingmin Han,Bin Liu,Zhiyong Li,Qinghai Ji,Lijun Tang,Zhiyong Deng,Yong Ding,Wei Fu,Xianhe Xie,Linfa Li,Xiaohui He,Zhongwei Lv,Qingjie Ma,Zan Shen,Zhuming Guo,Zhendong Chen,Yali Cui,Jian Tan,Zairong Gao,Shanghua Jing,Keyi Lu,Xianyang Luo,Yuan Zhang,Yong Fang,Zhendong Li,Yizhuang Cheng,Shangtong Lei,Sha Luan,Guang Chen,Guihua Wang,Liqing Wu,Lingling Liu
DOI: https://doi.org/10.1158/1078-0432.ccr-22-3613
IF: 13.801
2023-05-17
Clinical Cancer Research
Abstract:Purpose: The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the phase II study. We aimed to further evaluate the antitumour activity and safety of donafenib in Chinese RAIR-DTC patients. Patients and Methods: This multicenter, double-blind, placebo-controlled, phase III study enrolled 191 patients with progressive RAIR-DTC and randomized in a ratio of 2:1 to donafenib (300 mg twice daily, n=128) or matched placebo (n=63). An open-label donafenib treatment period was allowed upon disease progression. The primary endpoint was progression-free survival (PFS) assessed by the independent review committee. The second endpoints include objective response rate (ORR), disease control rate (DCR), safety, etc. Results: Donafenib demonstrated prolonged median PFS over placebo (12.9 vs. 6.4 months, HR 0.39, 95% CI 0.25-0.61, p<0.0001) in Chinese RAIR-DTC patients. Improved ORR (23.3% vs. 1.7%, p=0.0002) and DCR (93.3% vs. 79.3%,p=0.0044) were observed in the donafenib group over placebo. For donafenib, the most common grade ≥3 treatment-related adverse events included hypertension (13.3%) and hand-foot syndrome (12.5%), 42.2% underwent dose reduction or interruption and 6.3% experienced discontinuation. Conclusions: Donafenib was well-tolerated, and demonstrated clinical benefit in terms of improved PFS, ORR and DCRin patients with RAIR-DTC. The results suggest that donafenib could be a new treatment option for RAIR-DTC patients.
oncology